Boehringer Takes Out Option For Cystic Fibrosis Gene Therapy

06 Aug 2018

The German major is making its first foray into gene therapy and is looking to license a new viral vector-based product that could create a new therapeutic pathway for CF patients, regardless of their mutations.

Mountain — BI Finds A New Field With Gene Therapy • Source: Shutterstock

A long-time leader in the respiratory field, Boehringer Ingelheim GMBH has teamed up with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Oxford BioMedica PLC to develop a long-term treatment aimed at correcting the underlying genetic causes of the devastating lung disease.

The German group has received an option to license the exclusive global rights to develop, manufacture, register and commercialize a lentiviral vector-based gene therapy for CF

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.